[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cystic-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cystic-lesions":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,72,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100584820","a-study-for-the-pancystpro-assay-in-the-management-of-pancreatic-cystic-lesions-100584820",false,"NCT06894329","A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions","Clinical Utility Study to Determine Impact of PanCystPro Assay on Physician Decision-making in the Management of Pancreatic Cystic Lesions","PanAMP","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Cross sectional imaging studies demonstrating a pancreatic cyst at least 12 mm in size where fluid sampling can aid in patient's management\n* Written informed consent.\n* The patient will be undergoing EUS with anticipated FNA extraction as part of standard patient care.\n\nExclusion Criteria:\n\n* Patients diagnosed with pancreatic cancer.\n* Pregnant or lactating females.\n* Patients with contraindications to moderate or deep procedural sedation (necessary for the conduct of the endoscopic ultrasound) like major cardiorespiratory illness.\n* Patients with contraindications to FNA of a pancreatic cyst like being on blood thinners.","ALL","18 Years",{"count":20,"type":21},50,"ESTIMATED","12 Months","OBSERVATIONAL","The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered \"Non-mucinous\" or \"Mucinous\". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.",[26],"Pancreatic Cystic Lesions","RECRUITING","2026-03-12",{"date":30,"type":31},"2026-03-16","ACTUAL",{"date":33,"type":31},"2026-02-17",{"date":35,"type":21},"2027-06-30",{"name":37,"class":38},"Amplified Sciences Inc","INDUSTRY",3,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":50,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100626755","ai-powered-precision-decision-making-for-pancreatic-diseases-100626755","NCT07439757","AI-Powered Precision Decision-Making for Pancreatic Diseases","A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT","Inclusion Criteria:\n\n* Clinically suspected pancreatic disease.\n* Scheduled to undergo contrast-enhanced CT.\n* Signed informed consent form indicating agreement to participate.\n\nExclusion Criteria:\n\n* History of pancreatic surgery.\n* Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal\u002Fhepatic dysfunction.\n* Suboptimal image quality affecting diagnosis.\n* Concurrent participation in another interventional clinical trial.\n* Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.","80 Years",{"count":49,"type":21},2000,"1 Year","This multicenter clinical trial evaluates an artificial intelligence (AI) system designed to assist in the diagnosis and management of pancreatic diseases. Using contrast-enhanced CT scans, the study compares the AI's recommendations against the decisions of experienced clinicians to verify the system's accuracy and safety in a real-world setting. Patients are categorized into three management groups: Intervention (surgery\u002Ftreatment), Intensive Surveillance (close monitoring), or Routine Surveillance (standard follow-up). The primary goal is to determine if the AI system can reliably classify patients, reduce the risk of missing malignant lesions, and prevent unnecessary surgeries, thereby improving clinical decision-making for pancreatic conditions.",[53,54,55,26,56,57,58],"Pancreatic Cancer","Diagnose Disease","IPMN, Pancreatic","Chronic Pancreatitis","Pancreatic Neuroendocrine Tumor","Acute Pancreatitis (AP)",[60],"Artificial Intelligence (AI), Deep Learning, Contrast-Enhanced CT, Multicenter Clinical Trial, Real-World Study","2026-02-23",{"date":63,"type":31},"2026-02-27",{"date":65,"type":21},"2026-03-01",{"date":67,"type":21},"2029-10-31",{"name":69,"class":70},"Changhai Hospital","OTHER",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":50,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":71},"100258735","a-prospective-study-to-identify-predictive-biological-markers-in-blood-and-cyst-fluid-aspirates-from-patients-with-pancreatic-cyst-lesions-100258735","NCT02647177","A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions","Inclusion Criteria:\n\n* Diagnosis of Pancreatic Cystic Lesions (PCLs) or Acute Pancreatitis (AP) or chronic pancreatitis(CP) or Pancreatic Cancer (PC) (any stage\u002Fgrade) or congenital developmental anomalies of the pancreas.\n* Any combination of the diagnoses above.\n* Patients must provide written informed consent for the collection of blood specimens for research purposes.\n* Patients with PCLs must provide informed consent for collection of excess cyst fluid aspirate remaining after testing for routine standard of care\n* Patients with pancreatic Cystic Lesions (PCLs) or AP or CP or PC (any stage\u002Fgrade) or congenital developmental anomalies of the pancreas undergoing surgery must provide informed consent for collection of surgical specimen\n\nExclusion Criteria:\n\n* Patients with co-existing malignancies of other organs (or prior history of such)\n* Patients unable to provide informed consent\n* Patients unable to complete follow up","100 Years",{"count":80,"type":21},1000,"The purpose To determine the diagnostic potential of various biological markers in blood and cyst fluid aspirates from patients with Pancreatic Cystic Lesions (PCLs).\n\nResearch design This is a 10-year prospective cohort and pancreatic cyst fluid repository study enrolling all patients diagnosed with pancreatic cyst and undergoing the cyst aspiration.\n\nProcedures to be used Blood Sample Cyst Fluid Sample\n\nData Collection:\n\nMedical Record Number Demographics (age, sex, gender, race) Contact information History of alcohol use and IV and other recreational drugs and narcotics use\u002Fabuse Medication history Past hospitalizations, diagnoses, and treatment Physical examination findings Imaging data of abdominal and chest regions, including and not limited to ultrasonography, magnetic resonance imaging (MRI), computed tomography (CT) Future admissions, diagnoses, treatment including histopathological findings of resected specimens and blood reports End of study data: clinical progression of disease, cyst size, wall thickening, calcification, communication with pancreatic duct, string sign, cytology, immunohistochemical findings, assay levels of lipase, amylase CEA (carcinoembryonic antigen), carbohydrate antigen19-9 (CA 19-9), and other biomarkers.\n\nRisks and potential benefits The risks associated with this study are slight discomfort or bruising from the blood sampling and the possible loss of confidentiality if the patient data or information is inadvertently disclosed outside of this study. The patient will not receive any additional benefit from the study aside from those received as part of routine standard of care.\n\nImportance of knowledge that may reasonably be expected to result The knowledge gained from this study may benefit other patients with Pancreatic Cyst Lesions in the future.",[26],"2025-08-14",{"date":85,"type":31},"2025-08-15",{"date":87,"type":31},"2015-05",{"date":89,"type":21},"2027-04",{"name":91,"class":70},"The University of Texas Health Science Center, Houston",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100589464","predicting-cancer-in-pancreatic-cystic-lesions-through-artificial-intelligence-100589464","NCT06954753","Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence","Deep Learning for Malignant Degeneration Prediction of Pancreatic Cystic Lesions - Beyond High-risk Stigmata","Inclusion Criteria:\n\n* Patients diagnosed with PCL(s ) who underwent pancreatic surgery in one of the participant centers. Surgical indication must adhere to at least one of current guidelines on PCLs management (6), based on clinical, biochemical, and radiological (MR and\u002For EUS) features.\n* Pancreatic surgery B83performed for supposed increased risk of cyst(s) malignant degeneration following current guidelines on PCLs management (6).\n* Absence of clinical, biochemical, radiological, and anatomopathological evidence of pancreatic cancer at pancreatic surgery.\n* Non-opposition to the anonymous data processing by the included patients.\n\nExclusion Criteria:\n\n* Patients presenting with evidence of pancreatic cancer at surgery.\n* PCL(s) diagnosis and treatment performed without one between EUS and pancreatic MR. surgery performed in the absence of the criteria proposed by current guidelines.\n* Unavailability of both preoperative EUS and pancreatic MR data.\n* Unavailability of postoperative PCL(s) anatomopathological analysis results.\n* SBO diagnosis performed without CT-scan.",{"count":100,"type":21},250,"This international, multicenter retrospective study aims to develop a deep learning (DL)-based predictive model to identify malignant transformation in pancreatic cystic lesions, improving upon current clinical guidelines. The model will integrate clinical, biochemical, and multimodal imaging data. Several 3D convolutional neural networks will be trained using advanced preprocessing, data augmentation, and hybrid fusion techniques. Model performance will be compared to that of existing international guidelines. The study involves no additional procedures for patients and adheres to strict data anonymization and privacy regulations.",[53,26],"NOT_YET_RECRUITING","2025-04-30",{"date":106,"type":31},"2025-05-02",{"date":108,"type":21},"2025-06-01",{"date":110,"type":21},"2026-12-31",{"name":112,"class":70},"Centre Hospitalier Universitaire de Nice"]